Psychedelics like psilocybin are being researched in their potential to alleviate anxiety and depression in terminal cancer patients and veterans with PTSD. The early stages of research are being carefully chosen and build upon successful cannabinoid treatment in cancer patients.
Studies on psychedelic drugs such as psilocybin and MDMA have been successful in treating depression and other mental illnesses. Researchers at prestigious institutions, such as Johns Hopkins and NYU, have seen a high number of patients in remission from depression after taking the drugs.
Visit clinicaltrials.gov to find out about the ongoing research on psilocybin, MDMA, or psychedelic drugs. Over 50 studies, with just psilocybin, are ongoing now, mostly conducted in the context of a specific study, under the right framework of having a team.
The history of psychedelic research has been problematic in many ways and Timothy Leary has been blamed for many of the problems that emerged in relation to psychedelic drug use. However, the history of psychedelics was also profoundly elitist and it's important that there are people carefully monitoring what's happening in this important time in history.
A preliminary study showed that 80% of participants who used psilocybin and cognitive behavioral therapy were confirmed abstinent from smoking at the 6-month mark. The efficacy of this combination as a smoking cessation tool may be more successful than other traditional methods, such as the patch.
There is overlapping evidence that the use of psychedelic drugs creates wild and unusual experiences, reportedly healing depressed people back to normality. This has encouraged a group of scientists to embark on studies in an attempt to disburse psychedelic drugs on the market for treating depression.